WallStSmart

Merck & Company Inc (MRK)vsSight Sciences Inc (SGHT)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 76124% more annual revenue ($67.38B vs $88.39M). MRK leads profitability with a 3.6% profit margin vs -32.1%. MRK earns a higher WallStSmart Score of 42/100 (D).

MRK

Hold

42

out of 100

Grade: D

Growth: 3.3Profit: 6.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

SGHT

Avoid

27

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 6.7Quality: 6.0
Piotroski: 5/9Altman Z: -3.15
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-74.0%)

Margin of Safety

-74.0%

Fair Value

$84.93

Current Price

$144.52

$59.59 premium

UndervaluedFair: $84.93Overvalued
SGHTUndervalued (+33.3%)

Margin of Safety

+33.3%

Fair Value

$8.29

Current Price

$10.59

$2.30 discount

UndervaluedFair: $8.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$362.27B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Free Cash FlowQuality
$5.52B8/10

Generating 5.5B in free cash flow

SGHT1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
25.2%8/10

Revenue surging 25.2% year-over-year

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Return on EquityProfitability
5.5%3/10

ROE of 5.5% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Debt/EquityHealth
1.203/10

Elevated debt levels

SGHT4 concerns · Avg: 3.3/10
Price/BookValuation
11.9x4/10

Trading at 11.9x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$601.92M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-57.8%2/10

ROE of -57.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : SGHT

The strongest argument for SGHT centers on Revenue Growth. Revenue growth of 25.2% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 148.4x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Bear Case : SGHT

The primary concerns for SGHT are Price/Book, EPS Growth, Market Cap.

Key Dynamics to Monitor

MRK profiles as a value stock while SGHT is a growth play — different risk/reward profiles.

SGHT carries more volatility with a beta of 2.40 — expect wider price swings.

SGHT is growing revenue faster at 25.2% — sustainability is the question.

MRK generates stronger free cash flow (5.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (42/100 vs 27/100). SGHT offers better value entry with a 33.3% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Sight Sciences Inc

HEALTHCARE · MEDICAL DEVICES · USA

Sight Sciences Inc. (SGHT) is an innovative medical technology company specializing in the advancement of treatments for ocular diseases, with a particular emphasis on glaucoma management through both surgical and non-surgical approaches. The company’s diverse product portfolio, supported by a robust intellectual property framework, positions it favorably as demand for minimally invasive ophthalmic therapies escalates. By focusing on enhancing patient outcomes and refining its distribution network, Sight Sciences is set to capture significant market share in the evolving healthcare landscape, making it a noteworthy opportunity for institutional investors seeking growth in the medical technology sector.

Want to dig deeper into these stocks?